Apidra doesn’t warrant its own line in Sanofi’s financial reports, and the reductions don’t include Sanofi's Toujeo, a more concentrated version of insulin glargine that offers less frequent ...

The Europe-wide approval is the first ever insulin treatment licensed through the European Medicines Agency's biosimilar pathway, and the fourth diabetes product approved in the EU from the Lilly ...

The growth trajectory of the Apidra market is closely linked to the rising prevalence of diabetes, which is accelerating demand for rapid-acting insulin treatments like Apidra. Diabetes ...